ISSN: 2642-6250
Authors: Todic MR*
Medical science perceives randomized clinical trials (RCT) as the gold standard in the development of new drugs and source of providing valuable new treatment options. RCT results are indisputably used in the production of therapeutic guidelines and healthcare policy making. The health authorities of most developed countries are aware of the benefits of large-scale clinical trials. Thus, their websites often include sections dedicated to those. Issues they typically address include the application process for clinical trials or the potential benefits and risks for the participants. It seems that potential benefits for patients participating in large-scale clinical trials may vary greatly depending of the level of the health care available locally. In less developed countries, this is one of the ways for patients to have access to new, otherwise unavailable drugs. It is agreed that due to high level of regulation of this type of research patients as participants in clinical trials should be provided with direct health benefits, under the controlled risks that are not be greater than those associated with routine medical care or a disease progression.
Keywords:
